Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.
Minoxidil may age skin by slowing collagen synthesis, but using collagen peptides and a basic skincare routine might counteract this. Foam minoxidil could reduce systemic absorption and avoid alcohol-related side effects.
The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.
The user is concerned about hair loss despite using oral finasteride, oral minoxidil, and topical minoxidil. They are seeking advice on additional blood tests to identify potential causes.
The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.
The conversation discusses the belief that zinc, caffeine, and weightlifting may contribute to hair loss by increasing DHT levels. The original poster plans to reduce zinc and caffeine intake and stop weightlifting to see if it improves their hair condition.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
A user is seeking help to purchase and ship Alpecin DMG to the United States due to issues with eBay sellers. They prefer Alpecin DMG over minoxidil because of concerns about minoxidil's effects on insulin production, as they have diabetes.
User discusses Alfatradiol (17a-Estradiol) as a potential hair loss treatment with mixed results. Concerns include low dosage, receptor theory, and possible increased aromatase activity on scalp.
The conversation discusses using Rogain foam as a solvent for topical finasteride due to an allergy to propylene glycol. The foam's ingredients, including alcohol SD 40B, are considered suitable for dissolving finasteride for easier application without skin irritation.
Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.
The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.
The post discusses using Mucuna pruriens, essential oils, and dermarolling for hair loss treatment. The user also mentions pausing testosterone-boosting herbs due to side effects like acne and hair loss.
The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.
The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
The conversation discusses various theories and suggestions for hair loss, with a focus on DHT as the primary cause. Treatments mentioned include Minoxidil, finasteride, and RU58841.
Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.
Finasteride may cause elevated liver enzymes, potentially leading to liver issues, though this is rare. Users should monitor liver function and consider topical alternatives if liver sensitivity occurs.
Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.
The conversation is about a user suspecting excessive soy consumption caused their hair loss and considering removing soy from their diet. Another user suggests balancing soy with other nutrients, as soy is generally thought to protect hair.
A dermatologist recommended a new supplement containing annurca apple, which reportedly doubles hair density and increases keratin after 60 days, to be used with finasteride. Some users are skeptical, considering it potentially ineffective or a marketing ploy, while others are open to trying it if it proves effective and affordable.
The user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and ask for advice on shipping within the EU and product quality, while also mentioning their current hair loss treatment involves mixing RU with Stemoxydine and Alfatradiol.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
Hair loss is linked to scalp fibrosis and tension, which result from chronic mechanical stress and androgenic signaling. Treatments include blocking androgens with finasteride, promoting hair growth with topical minoxidil, and improving scalp mobility through exercises.
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
The conversation is about using alfatradiol as a hair loss treatment. The user is considering adding it to their regimen because it is safe, mild, and easily available in Europe.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.